Commercialization and Technology Transfer of Organ-Humanized Mice
First written in FY2016. 3 of 7 entries say "Advanced", first in FY2020. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「Among these, preparations were under way to commercialise the liver-humanised mouse, which reflects human organ function and is expected to be used in more accurate preclinical studies, including studies of drug efficacy and metabolism, but development has been delayed due to the optimal allocation of management resources.」
Although preparations for commercialising liver-humanised mice are continuing, the disclosure continues to report development delays resulting from the optimal allocation of management resources. - FY2025SoftenedAnnual report
「Among these, preparations were under way to commercialise the liver-humanised mouse, which reflects human organ function and is expected to be used in more accurate preclinical studies, including studies of drug efficacy and metabolism, but development has been delayed due to the optimal allocation of management resources.」
The Company explicitly states that development was delayed due to the optimal allocation of management resources in relation to preparations for commercialising liver-humanised mice, which began in the previous fiscal year. - FY2024AdvancedAnnual report
「Among these, the liver-humanised mouse, which reflects human organ function, is expected to be used in more accurate preclinical studies, including studies of drug efficacy and metabolism, and preparations for commercialisation began in December 2023.」
Preparations for commercialising organ-humanised mice began in December 2023. - FY2021AdvancedAnnual report
「The Company changed its mouse business from the Company to 安評センター and will accelerate development of the various humanised model mice currently in progress by utilising 安評センター's animal-testing technology.」
For development of humanised model mice, the Company is moving toward a structure that will accelerate development through the transfer of the business to 安評センター and the use of its animal-testing technology. - FY2020AdvancedAnnual report
「For the purpose of elucidating the mechanism of COVID-19 infection and disease onset, we began developing mice in which the exon of the receptor necessary for infection by the virus had been humanised, using our proprietary exon-humanised mouse technology.」
As part of its humanised mouse initiatives, the Company began developing exon-humanised mice to elucidate the mechanism of COVID-19 infection. - FY2017RestatedAnnual report
「In addition, we will promote the introduction of organ-humanised mice and disease-model mice that express diseases similar to those in humans, and pursue initiatives toward collaborative businesses with the CRO business.」
The Company continues to introduce organ-humanised mice and disease-model mice and collaborate with the CRO business. - FY2016First statedAnnual report
「In addition, we intend to promote and implement technology transfer aimed at commercialising "organ-humanised mice" during the fiscal year.」
Against the backdrop of joint research with Kumamoto University, the Company has indicated a policy of pursuing technology transfer aimed at commercialising organ-humanised mice during the fiscal year.